Skip to content
qps logo

Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
Contact Us → Apply Now →

  • Home
  • About
    • Staff
    • Safety
    • FAQs
    • Location
    • Blog
  • Studies
    • Available Studies
    • Ongoing Studies
  • Enroll
    • Application
    • Study Process
    • How to Participate
  • Join Our Team
  • Referral Program
  • Contact
qps logo

Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
Contact Us → Apply Now →

  • Home
  • About
    • Staff
    • Safety
    • FAQs
    • Location
    • Blog
  • Studies
    • Available Studies
    • Ongoing Studies
  • Enroll
    • Application
    • Study Process
    • How to Participate
  • Join Our Team
  • Referral Program
  • Contact

About Clinical Research
Study #57123

This Clinical Research Study will be evaluating the safety and effectiveness of an investigational COVID-19 and flu vaccine in healthy adults.

Are You a Good Fit?

Men and Women

Healthy

50 years of age and older

Body Mass Index (BMI) 35.0 kg/m2 and lower

  • Receive up to $407 for your participation in this study
Happy older couple hugging

What are the Time Requirements?

This study will consist of one screening/dosing and two outpatient return visits. Study dates are as follows:
Group 1 (Phase 1)
Visit Dates
Outpatient Visit
Wednesday, January 31, 2024
Return
Thursday, February 29, 2024
Monday, July 29, 2024

How Much: $407

Group 2 (Phase 1)
Visit Dates
Outpatient Visit
Friday, February 2, 2024
Return
Saturday, March 2, 2024
Wednesday, July 31, 2024

How Much: $407

Group 3
Visit Dates
Outpatient Visit
Friday, February 23, 2024 8:00 am
Return
Saturday, March 23, 2024 1:00 pm
Wednesday, August 21, 2024 1:00 pm

How Much: 407

BMI Calculator

BMI Calculator Simple

Weight

Unit of measurement*
cm
kg
ft
in
lbs

BMI

Middle Age Couple

All study dates are tentative and subject to change.

We will update the clinical research studies list weekly. Be sure to check with us either by calling or going online. Call (417) 831-2048 or visit 417studies.com for more information. You can also visit the Screening and Recruitment Center located at 2025 W. Sunshine Street, L-109. Office hours are Monday through Friday from 8 a.m. to 5 p.m.

• Eligible individuals must willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures.

• Healthy participants are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for the study.

• Eligible individuals must be capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions.

• A female participant is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following conditions applies:
• Postmenopausal females are defined as no menses for 12 months without an alternative medical cause.
• Is not a WOCBP
• Premenopausal female with 1 of the following:
• Documented hysterectomy;
• Documented bilateral salpingectomy;
• Documented bilateral oophorectomy.

For individuals with permanent infertility due to a medical cause other than the above (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

• Is a woman of Child Bearing Potential
• Highly Effective Methods That Have Low User Dependency:
• Implantable progestogen only hormone contraception associated with inhibition of ovulation.
• Intrauterine device.
• Intrauterine hormone releasing system.
• Bilateral tubal occlusion.
• Vasectomized partner:
• Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis
cycle is approximately 90 days.

• Highly Effective Methods That Are User Dependent:
• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
• Oral;
• Intravaginal;
• Transdermal.
• Progestogen only hormone contraception associated with inhibition of ovulation:
• Oral
• Injectable
• Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the
study and the preferred and usual lifestyle of the participant.

• Other Effective Methods
• Progestogen only oral hormonal contraception where inhibition of ovulation is not the primary mode of action.
• Male or female condom, with or without spermicide.
• Cervical cap, diaphragm, or sponge with spermicide.
• A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier methods

If you have previously submitted an application, call 417-831-2048 to enroll. Or click on the button below to submit your application now.

Apply Online Now

Signup for our newsletter!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Important Links

  • Home
  • About
  • Our Studies
  • Ongoing Studies
  • Enroll
  • FAQs
  • Referral Program
  • Join Our Team
  • Blog
  • Contact
  • Privacy Policy

QPS Missouri

QPS Study Campus
1820 W. Mount Vernon Street
Springfield, MO 65802

QPS Screening and Recruitment Center
2025 W. Sunshine Street, L-109
Springfield, MO 65807

Hours of Operation:
Monday – Friday
8 a.m. – 5 p.m.

Call us at 417.831.2048

Employees

  • Employee Portal

qps bird logo outline

Copyright © 2025 QPS Missouri | All Rights Reserved